Ian S. Mitchell
Genentech
22 Papers
292 Citations
Ian S. Mitchell is an academic researcher from Genentech. The author has contributed to research in topics: Protein kinase B & Cyclopentanes. The author has an hindex of 10, co-authored 20 publications.
Chat about Author
Papers
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
James F. Blake,Rui Xu,Josef R. Bencsik,Dengming Xiao,Nicholas C. Kallan,Stephen T. Schlachter,Ian S. Mitchell,Keith Lee Spencer,Banka Anna L,Eli M. Wallace,Susan L. Gloor,Matthew Martinson,Richard Woessner,Guy Vigers,Barbara J. Brandhuber,Jun Liang,Brian Safina,Jun Li,Birong Zhang,Christine Chabot,Steven Do,Leslie Lee,Jason Oeh,Deepak Sampath,Brian Lee,Kui Lin,Bianca M. Liederer,Nicholas J. Skelton +27 more
TL;DR: Biological studies with one 6,7-dihydro-5H-cyclopenta[d]pyrimidine compound, 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated.
185
Patent
Akt protein kinase inhibitors
Ian S. Mitchell,Keith Lee Spencer,Stengel Peter J,Yongxin Han,Nicholas C. Kallan,Mark C. Munson,Guy Vigers,James F. Blake,Anthony Piscopio,John A. Josey,Scott Miller,Dengming Xiao,Rui Xu,Chang Rao,Bing Wang,April L. Bernacki +15 more
- 19 Nov 2004
TL;DR: In this paper, a formula for resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group.
83
Discovery of pyrrolopyrimidine inhibitors of Akt.
James F. Blake,Nicholas C. Kallan,Dengming Xiao,Rui Xu,Josef R. Bencsik,Nicholas J. Skelton,Keith Lee Spencer,Ian S. Mitchell,Richard Woessner,Susan L. Gloor,Tyler Risom,Stefan D. Gross,Matthew Martinson,Tony Morales,Guy Vigers,Barbara J. Brandhuber +15 more
TL;DR: A series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts.
64
Patent
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
Josef R. Bencsik,James F. Blake,Nicholas C. Kallan,Ian S. Mitchell,Keith Lee Spencer,Dengming Xiao,Rui Xu,Christine Chabot,Jun Liang,Brian Safina +9 more
- 03 Jul 2008
TL;DR: In this article, the present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof.
48
Patent
Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
Ian S. Mitchell,James F. Blake,Rui Xu,Nicholas C. Kallan,Dengming Xiao,Keith Lee Spencer,Josef R. Bencsik,Jun Liang,Brian Safina,Birong Zhang,Christine Chabot,Steven Do,Eli M. Wallace,Banka Anna L,Stephen T. Schlachter +14 more
- 05 Jul 2007
TL;DR: In this article, the present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I).
35